BMO Capital lowered the firm’s price target on Sarepta (SRPT) to $25 from $50 and keeps a Market Perform rating on the shares. Although the Elevidys pause puts significant financial pressure on Sarepta near-term, this is currently the optimal decision, as refusal to comply with the FDA would trigger high regulatory risk across Sarepta’s programs and limited or slow Elevidys uptake due to increased scrutiny from physicians, patients, payers, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $11 from $18 at Piper Sandler
- Sarepta Stock (SRPT) Could Crash to $0, Warns Wainwright Analyst
- Sarepta Therapeutics’ Shipment Pause of Elevidys: Strategic Move Amidst Regulatory Concerns
- Sarepta downgraded to Equal Weight from Overweight at Barclays
- Sarepta announces voluntary pause of Elevidys shipments in the U.S.